Alerta

Oragenics Inc. (OGEN)

NYSE American: OGEN · Precio en tiempo real · USD

0.55

+0.00 (0.00%)

Al cierre: Aug 19, 2026, 12:36 PM

0.00% (1D)

Precio de compra	n/a
Capitalización de mercado	2.47M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-10.08M
Beta	n/a
EPS (TTM)	0.98
Ratio PER (TTM)	0.56
Adelante PE	-0.05
P/B (TTM)	0.39
P/S (TTM)	n/a
Earnings Date	n/a

Precio de venta	n/a
Volumen	4,876
Volumen medio (20D)	38,916
Abierto	0.55
Anterior Cerrar	0.55
Rango del día	0.55 - 0.55
Rango de 52 semanas	0.48 - 1.45
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de OGEN

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene ampli...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Feb 25, 2004

Empleados 3

Bolsa de Valores NYSE American

Símbolo bursátil OGEN

Sitio web https://www.oragenics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Oragenics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -9.84M, una disminución de -6.86%.

Estados financieros

Sorpresa de resultados

Oragenics ha publicado sus resultados trimestrales en May 12, 2023:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -42.3 supera las estimaciones en 47.71, con 53.01% Crecimiento interanual.

Noticias

6 meses hace · TipRanks

Oragenics previews targeted milestones for 2026

Oragenics (OGEN) previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and onl...

6 meses hace · TipRanks

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial d...

9 meses hace · Associated Press Finance

Oragenics: Q3 Earnings Snapshot

SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $3.1 million in its third quarter.

10 meses hace · Pharmaceutical Technology

Oragenics partners Receptor.AI for brain health candidate portfolio

The partnership will harness AI modelling techniques to determine the ideal receptor binding profiles for new compounds.

Oragenics Inc. (OGEN)